ConductScience.org, home

Paper21079425

Adverse events with isoniazid preventive therapy: experience from a large trial.

Grant AD and 5 others. AIDS, 2010. Cited by 40 papers, by iCite.

Cite this record

ConductScience Library. Adverse events with isoniazid preventive therapy: experience from a large trial. Papers, record 21079425. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21079425

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Adverse events with isoniazid preventive therapy: experience from a large trial.
PubMed
Journal
AIDS
PubMed
Year
2010
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
40
iCite
Relative citation ratio, by iCite
1.39
iCite
Revised in PubMed
2026-01-28
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Grant ADAlison D
2Mngadi KTKathryn T
3van Halsema CLClare L
4Luttig MMMariëtha M
5Fielding KLKatherine L
6Churchyard GJGavin J

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AIDS-Related Opportunistic InfectionsMajor topic
Antitubercular AgentsMajor topic
HIV InfectionsMajor topic
IsoniazidMajor topic
TuberculosisMajor topic
Adult
Female
Humans
Male
Mining
Prevalence
Radiography, Thoracic
South Africa

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Department of HealthUnited KingdomPubMed

Source PubMed

Download CSV of grants

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.

PMIDTitleJournalYearIn PapersSource
41550517Safety and Effectiveness of Long-Term Isoniazid Treatment for the Prevention of Tuberculosis in High-Risk Dialysis Patients.Kidney Int Rep2026https://conductscience.org/library/papers/41550517PubMed
41259110Adverse Drug Reactions Related to Isoniazid Preventive Therapy Among Persons Living With HIV on Dolutegravir-Based Regimens in Uganda Between July 2019 and March 2020.J Acquir Immune Defic Syndr2026https://conductscience.org/library/papers/41259110PubMed
39945250Latent Tuberculosis Screening and Active Tuberculosis Disease Development in People Living with HIV: A Multicenter Retrospective Cohort Study in Turkiye.Curr HIV Res2025https://conductscience.org/library/papers/39945250PubMed
39364056Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement.Front Pharmacol2024https://conductscience.org/library/papers/39364056PubMed
37289412Liver Injury Following Isoniazid Preventive Therapy in HIV Patients Attending Halibet National Referral Hospital, Eritrea: A Prospective Cohort Study.Drugs Real World Outcomes2023https://conductscience.org/library/papers/37289412PubMed
35777873Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial.BMJ Open2022https://conductscience.org/library/papers/35777873PubMed
32875123Tuberculosis preventive therapy (TPT) to prevent tuberculosis co-infection among adults with HIV-associated cryptococcal meningitis: A clinician's perspective.J Clin Tuberc Other Mycobact Dis2020https://conductscience.org/library/papers/32875123PubMed
30758779Tolerability of Isoniazid Preventive Therapy in an HIV-Infected Cohort of Paediatric and Adolescent Patients on Antiretroviral Therapy from a Resource-Limited Setting: A Retrospective Cohort Study.Drugs Real World Outcomes2019https://conductscience.org/library/papers/30758779PubMed
30073087Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea.Pharmacol Res Perspect2018https://conductscience.org/library/papers/30073087PubMed
29692453Controversies in the Management of Cutaneous Adverse Drug Reactions.Indian J Dermatol2018https://conductscience.org/library/papers/29692453PubMed
29471904Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.Int J Tuberc Lung Dis2018https://conductscience.org/library/papers/29471904PubMed
28775944Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe.Public Health Action2017https://conductscience.org/library/papers/28775944PubMed
28147705"It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.AIDS Care2017https://conductscience.org/library/papers/28147705PubMed
27695679Dotting the Three I's for collaborative TB-HIV activities: evaluation of a pilot programme in Kathmandu, Nepal.Public Health Action2016https://conductscience.org/library/papers/27695679PubMed
27516382Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.Clin Infect Dis2016https://conductscience.org/library/papers/27516382PubMed
26323809Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.J Neurovirol2016https://conductscience.org/library/papers/26323809PubMed
26221405Successful diagnosis of hyperpyrexia induced by isoniazid in a child with suspected extra-pulmonary tuberculosis.Int J Clin Exp Med2015https://conductscience.org/library/papers/26221405PubMed
25700378Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion.Eur Respir J2015https://conductscience.org/library/papers/25700378PubMed
24957052Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study.BMC Pharmacol Toxicol2014https://conductscience.org/library/papers/24957052PubMed
24527412Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management.Asia Pac Allergy2014https://conductscience.org/library/papers/24527412PubMed

See all 25 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21079425

GET https://conductscience.org/api/papers/v1/21079425/cited_by?page=2